| Morningstar Fund Report | 13/04/2025 |  |
Janus Henderson Capital Funds plc - Global Life Sciences Fund Class I2 USD |
| Performance History | 31/03/2025 |
| Growth of 1,000 (GBP) | Advanced Graph |
 | Fund | 6.6 | 8.6 | 0.3 | 4.4 | -2.3 |
| +/-Cat | -2.9 | 13.2 | 3.5 | 3.4 | -0.7 |
| +/-B’mrk | -11.6 | 2.8 | 2.9 | 1.7 | -4.2 |
| Category: Sector Equity Healthcare | ||||||
| Category Benchmark: Morningstar Gbl Health TME ... | ||||||
| Key Stats | ||
| NAV 11/04/2025 | USD 59.86 | |
| Day Change | 1.78% | |
| Morningstar Category™ | Sector Equity Healthcare | |
| ISIN | IE0002141913 | |
| Fund Size (Mil) 11/04/2025 | USD 3544.84 | |
| Share Class Size (Mil) 11/04/2025 | USD 1089.99 | |
| Max Initial Charge | 2.00% | |
| Ongoing Charge 31/07/2024 | 1.56% | |
| Investment Objective: Janus Henderson Capital Funds plc - Global Life Sciences Fund Class I2 USD |
| The Fund’s investment objective is long-term growth of capital. It pursues its objective by investing at least 80% of its net asset value in equities (also known as company shares) located anywhere in the world and selected for their growth potential. The Fund will invest at least 80% of its net asset value in companies that the relevant Sub-Investment Adviser believes have a life sciences orientation. Generally speaking, the “life sciences” relate to maintaining or improving quality of life. Thus, companies with a “life sciences orientation” include companies engaged in research, development, production or distribution of products or services related to health and personal care, medicine or pharmaceuticals. Such companies may also include companies that the relevant Sub-Investment Adviser believes have growth potential mainly as a result of particular products, technology, patents or other market advantages in the life sciences. |
| Returns | |||||||||||||
|
| Management | ||
Manager Name Start Date | ||
Andy Acker 01/05/2007 | ||
Daniel Lyons 31/01/2023 | ||
Inception Date 31/03/2000 | ||
| Category Benchmark | |
| Fund Benchmark | Morningstar Benchmark |
| MSCI World/Health Care NR USD | Morningstar Gbl Health TME NR USD |
| Portfolio Profile for Janus Henderson Capital Funds plc - Global Life Sciences Fund Class I2 USD | 31/03/2025 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||
| Top 5 Holdings | Sector | % |
 Eli Lilly and Co |  Healthcare | 9.43 |
| UnitedHealth Group Inc | Healthcare | 6.90 |
| AstraZeneca PLC | Healthcare | 4.02 |
 Johnson & Johnson | Healthcare | 3.60 |
| Boston Scientific Corp | Healthcare | 3.14 |
 | ||
Increase Decrease  New since last portfolio | ||
| Janus Henderson Capital Funds plc - Global Life Sciences Fund Class I2 USD | ||
| Growth Of 1000 (GBP) | 31/03/2025 |
|
| Annual Returns (GBP) | 31/03/2025 | |||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 31/03 | |
| Price Return | 9.14 | 23.10 | 20.53 | 6.57 | 8.56 | 0.33 | 4.39 | -2.28 |
| +/- Category | 6.45 | 6.08 | 3.05 | -2.86 | 13.22 | 3.45 | 3.42 | -0.67 |
| +/- Category Index | - | - | - | -11.64 | 2.75 | 2.86 | 1.69 | -4.21 |
| % Rank in Category | 23 | 18 | 30 | 67 | 9 | 30 | 22 | 61 |
| Trailing Returns (GBP) | 11/04/2025 | ||
| Total Returns | +/- Category | +/- Category Index | |
| 1 Day | 1.78 | 1.99 | 1.10 |
| 1 Week | 1.00 | 3.64 | 1.91 |
| 1 Month | -7.87 | 0.38 | -0.60 |
| 3 Months | -11.81 | -0.47 | -3.11 |
| 6 Months | -16.17 | -3.25 | -3.86 |
| YTD | -9.28 | -0.96 | -3.91 |
| 1 Year | -10.66 | 0.09 | -3.64 |
| 3 Years Annualised | 0.84 | 5.58 | 1.57 |
| 5 Years Annualised | 6.47 | 3.30 | 0.79 |
| 10 Years Annualised | 6.35 | 1.45 | -0.41 |
| Category: Sector Equity Healthcare | |||
| Category Index: Morningstar Gbl Health TME NR USD | |||
| Quarterly Returns (GBP) | 31/03/2025 | |||
| Quarter 1 | Quarter 2 | Quarter 3 | Quarter 4 | |
| 2025 | -2.28 | - | - | - |
| 2024 | 9.29 | 1.61 | -0.95 | -5.09 |
| 2023 | -4.20 | 1.70 | -0.42 | 3.42 |
| 2022 | -2.55 | -0.90 | 6.50 | 5.55 |
| 2021 | -4.00 | 6.69 | 1.36 | 2.65 |
| 2020 | -8.22 | 22.17 | 0.04 | 7.45 |
| Morningstar Rating™(Relative to Category) | 31/03/2025 | ||||||||||||||||||||
| |||||||||||||||||||||
| Category : Sector Equity Healthcare | Click here to see our Methodology | ||||||||||||||||||||
| Volatility Measurements | 31/03/2025 | ||||||||||
| |||||||||||
| Modern Portfolio Statistics | 31/03/2025 | 31/03/2025 |
| Standard Index | Best Fit Index | |
| Morningstar Gbl Health TME NR USD | Morningstar Gbl Health TME NR USD | |
| 3-Yr Beta | 1.03 | 1.03 |
| 3-Yr Alpha | 1.75 | 1.75 |
| Investment Style Details | 31/03/2025 | ||||||||||||||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||
| Category: Sector Equity Healthcare | |||||||||||||||||||||||||||||||||||||||||
| Asset Allocation | 31/03/2025 |
| ||||||||||||||||||||||||||
| World Regions | 31/03/2025 | ||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||
| Category: Sector Equity Healthcare | |||||||||||||||||||||||||||||||||||||||||||
| Sector Weightings | 31/03/2025 | ||||||
| |||||||
| Category: Sector Equity Healthcare | |||||||
| Top 10 Holdings | 31/03/2025 |
| Portfolio NEW | |
| Total Number of Equity Holdings | 99 |
| Total Number of Bond Holdings | 0 |
| Assets in Top 10 Holdings | 41.82 |
| Name | Sector | Country | % of Assets | ||
| Eli Lilly and Co | | United States | 9.43 | ||
| UnitedHealth Group Inc | | United States | 6.90 | ||
| AstraZeneca PLC | | United Kingdom | 4.02 | ||
| Johnson & Johnson | | United States | 3.60 | ||
| Boston Scientific Corp | | United States | 3.14 | ||
| Abbott Laboratories | | United States | 3.10 | ||
| Sanofi SA | | France | 3.07 | ||
| Amgen Inc | | United States | 2.90 | ||
| AbbVie Inc | | United States | 2.84 | ||
| Vertex Pharmaceuticals Inc | | United States | 2.83 | ||
| Increase Decrease New since last portfolio | |||||
| Category: Sector Equity Healthcare | |||||
| Management | ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| |
| Biography | |
| Andy Acker is a Portfolio Manager on the Health Care and Biotech Teams at Janus Henderson Investors. He is also the Health Care Sector Lead. Andy was an assistant portfolio manager from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners. Andy received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honours from Harvard Business School. Andy holds the Chartered Financial Analyst designation and has 28 years of financial industry experience. |
|
| Fund Manager | Daniel Lyons |
| Manager Start Date | 31/01/2023 |
| Career Start Year | 1997 |
| Education |
| Rice University, B.A. |
| Stanford University, Ph.D. |
| |
| Biography | |
| Daniel Lyons is a Portfolio Manager on the Health Care and Biotech Teams at Janus Henderson Investors, a role he has held since 2018. He is also a Research Analyst on the US Small/Mid-Cap Growth Team since 2000 and focuses on biotechnology and life science tools sectors. Daniel started consulting for Janus in 1997 and joined the research team full time in 2000. Daniel received his bachelor of arts degree in biochemistry and chemistry from Rice University, graduating magna cum laude. He also earned a PhD from Stanford University’s programme in immunology and conducted postdoctoral research with a Nobel Laureate at the University of Colorado. He holds the Chartered Financial Analyst designation and has 24 years of financial industry experience. |
| Fees and Expenses | ||||||||||||
| ||||||||||||
| Purchase Details | ||||||||
| ||||||||
| ||||||||